Sign In
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- US Share Prices
- Stock Tips
- Share Chat
- FX
- News & RNS
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Faron Pharmaceuticals Share News (FARN)
FARN Share
Price
FARN Share
News
FARN Share
Chat
FARN Share
Trades
FARN
Live RNS
FARN Share
Charts
FARN Level 2
Console
FARN Live
Share Price
FARN Broker
Ratings
FARN Directors
Deals
FARN Financial
Diary
FARN
Fundamentals
FARN Short
Positions
FARN
Media
FARN Company
Research
FARN Company
Timeline
Share Price Information for Faron Pharmaceuticals (FARN)
Last checked at -
Last checked at 
Intraday Faron Pharmaceuticals Share Chart
Faron Pharmaceuticals Notes Study Supporting Clevegen Programme
LONDON (Alliance News) - Faron Pharmaceuticals Oy on Monday said an article published in the Journal of Immunology has outlined the functional role of the company's Clever-1 treatment, part of its Clevegen cancer immunotherapy antibody programme.
Faron, which floated in London earlier this month, said the data published in the study supported Clever-1 as an immuosuppresive molecule and supports the use of Clevegen as an immunotherapy product.
"We are working hard to advance our Clevegen programme, as announced recently, towards clinical use as a new onco-immunological alternative," said Faron Chief Executive Markku Jalkanen.
Shares in Faron were trading flat at 275.00 pence on Monday.
By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
Latest FARN News
- TRADING UPDATES: Quiz sales fall, names new CEO; Byotrol eyes AIM exit
3 Apr 2024 - UK shareholder meetings calendar - next 7 days
2 Apr 2024 - LONDON MARKET CLOSE: Stocks downbeat before central bank rate storm
18 Mar 2024 - Faron shares jump on encouraging trial data
18 Mar 2024 - Faron Pharmaceuticals shares jump on positive data from Bexmab study
18 Mar 2024 - AIM WINNERS & LOSERS: Clontarf raises GBP400,000; Faron jumps
18 Mar 2024 - EARNINGS AND TRADING: PensionBee nears profit; OptiBiotix Indian deal
13 Mar 2024 - Faron Pharmaceuticals reports year of clinical progress
13 Mar 2024
Related News
IN BRIEF: Faron Pharmaceuticals fined EUR30,000 by Nasdaq Helsinki
Faron Pharmaceuticals Ltd - Turku, Finland-based cancer drug developer - Says the Disciplinary Committee of Nasdaq Helsinki Ltd has imposed an EUR30,0...
WINNERS & LOSERS: James Cropper sees earnings up; Block sells stake
(Alliance News) - The following are the leading risers and fallers among London Main Market small-cap and AIM stocks on Tuesday.
Faron Pharmaceuticals News
TRADING UPDATES: Quiz sales fall, names new CEO; Byotrol eyes AIM exit
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:
LONDON MARKET CLOSE: Stocks downbeat before central bank rate storm
(Alliance News) - Stocks in London closed in the red on Monday, as tech gains in New York failed to make an impact ahead of several interest rate deci...
Faron shares jump on encouraging trial data
(Sharecast News) - Faron Pharmaceuticals announced further encouraging data from the first phase of its 'BEXMAB' trial on Monday, targeting higher-ris...
Faron Pharmaceuticals shares jump on positive data from Bexmab study
(Alliance News) - Faron Pharmaceuticals Ltd on Monday said a study showed more patients responding to treatment in a new readout of the Bexmab study f...
AIM WINNERS & LOSERS: Clontarf raises GBP400,000; Faron jumps
(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.
EARNINGS AND TRADING: PensionBee nears profit; OptiBiotix Indian deal
(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and not separately repor...
Faron Pharmaceuticals reports year of clinical progress
(Sharecast News) - Clinical-stage biopharmaceutical company Faron Pharmaceuticals reported a year of strong progress on Wednesday, with significant ov...
Follow the stocks
